Telix Pharmaceuticals (TLX) Intangibles (2023 - 2025)

Telix Pharmaceuticals (TLX) has reported Intangibles for 3 consecutive years, with $592.8 million the latest figure, recorded in Q4 2025.

• Quarterly Intangibles rose 101.72% year-over-year to $592.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $592.8 million (up 101.72% YoY) and the FY2025 annual result came in at $592.8 million, up 129.9% from the prior year.
• Intangibles rose to $592.8 million in Q4 2025 per TLX's latest filing, from $293.9 million in the prior quarter.
• Over the last five years, Intangibles for TLX reached as high as $592.8 million in Q4 2025 and fell as low as $77.4 million in Q4 2023.
• A 3-year average of $321.4 million and a median of $293.9 million in 2024 frame the typical range for Intangibles.
• Annual changes were most pronounced in 2024 — Intangibles jumped 279.47% — and 2025, when it jumped 101.72%.
• Year by year, Intangibles stood at $77.4 million in 2023, then soared by 279.47% to $293.9 million in 2024, then soared by 101.72% to $592.8 million in 2025.
• According to Business Quant data, Intangibles over the past three periods registered $592.8 million, $293.9 million, and $77.4 million for Q4 2025, Q4 2024, and Q4 2023 respectively.